Compound KTI-2338 Inhibits ACVR1 Receptor Signaling in Fibrodysplasia Ossificans Progressiva
Neeltje M Rosenberg, Lidiia Zhytnik, Lisanne E Wisse, Esmée Botman, Jennifer L Lachey, E Marelise W Eekhoff, Dimitra Micha, Ruggero Bettini · 2025
Read Compound KTI-2338 Inhibits ACVR1 Receptor Signaling in Fibrodysplasia Ossificans Progressiva by Neeltje M Rosenberg, Lidiia Zhytnik, Lisanne E Wisse, Esmée Botman, Jennifer L Lachey, E Marelise W Eekhoff, Dimitra Micha, Ruggero Bettini (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12736380.txt.
Description
Neeltje Rosenberg and co-authors test a new compound against a rare disease in which bone grows inside muscle and tendon. The disease locks joints over time and leaves patients immobile. A faulty gene leaves a growth receptor switched on, driving the stray bone.
The compound blocks that receptor's signaling in lab tests. The team profiled how strongly and how cleanly it acts. Blocking the altered receptor is a leading strategy in this disease, with several trials under way. A new entrant matters because current options are few and the disease starts in childhood. The lab profile decides whether the compound deserves animal and human tests. The report lays out that first evidence in full.
Catalog record
| CREATOR | Neeltje M Rosenberg, Lidiia Zhytnik, Lisanne E Wisse, Esmée Botman, Jennifer L Lachey, E Marelise W Eekhoff, Dimitra Micha, Ruggero Bettini |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 35 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |